IL17RC
interleukin 17 receptor C
This gene encodes a single-pass type I membrane protein that shares similarity with the interleukin-17 receptor (IL-17RA). Unlike IL-17RA, which is predominantly expressed in hemopoietic cells, and binds with high affinity to only IL-17A, this protein is expressed in nonhemopoietic tissues, and binds both IL-17A and IL-17F with similar affinities. The proinflammatory cytokines, IL-17A and IL-17F, have been implicated in the progression of inflammatory and autoimmune diseases. Multiple alternatively spliced transcript variants encoding different isoforms have been detected for this gene, and it has been proposed that soluble, secreted proteins lacking transmembrane and intracellular domains may function as extracellular antagonists to cytokine signaling.
provided by RefSeq
Biological Domains
Immune Response, Synapse
Pharos Class
Tclin
Summary of Evidence
This tab shows an overview of how the selected gene is associated with AD.
Genetic Association with LOAD
Indicates whether or not this gene shows significant genetic association with Late Onset AD (LOAD) based on evidence from multiple studies compiled by the ADSP Gene Verification CommitteeFalseBrain eQTL
Indicates whether or not this gene locus has a significant expression Quantitative Trait Locus (eQTL) based on an AMP-AD consortium studyTrueRNA Expression Change in AD Brain
Indicates whether or not this gene shows significant differential expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.TrueProtein Expression Change in AD Brain
Indicates whether or not this gene shows significant differential protein expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.No dataNominated Target
Indicates whether or not this gene has been submitted as a nominated target to Agora.False
AD Risk Scores
About AD Risk Scores
The TREAT-AD Center at Emory-Sage-SGC has developed a Target Risk Score (TRS) to objectively rank the potential involvement of specific genes in AD. The TRS is derived by summing two component risk scores, the Genetic Risk Score and the Multi-omic Risk Score, each of which is derived from a meta-analysis of multiple harmonized data sets. More information about the methodology used to define these risk scores is available here.
AD Risk Scores for IL17RC
The TRS for IL17RC, along with the component Genetic and Multi-omic Risk Scores, is shown here. The scores for IL17RC are superimposed on the genome-wide score distributions. If No Data is Currently Available is displayed for a score, that score was not calculated for IL17RC.
Biological Domain Classification
About Biological Domains
A biological domain represents a standardized area of biology defined by a set of discrete, biologically coherent GO terms. The TREAT-AD Center at Emory-Sage-SGC has defined nineteen biological domains associated with AD, and objectively mapped genes to those biological domains using GO term annotations. More information about the methodology used to define AD biological domains, and to generate genome-wide biological domain mappings, is available here.
Biological Domains for IL17RC
Select a biological domain on the left to see the list of GO terms that link IL17RC to it on the right. The percentage value displayed next to the currently selected biological domain indicates the proportion of IL17RC's total unique GO terms that map to the biological domain. The ratio displayed on the right indicates how many of the biological domain's total GO terms IL17RC is annotated with.